
Today on Pharmaceutical Processing
Roche to invest $50B in U.S. over next five years
Roche announced plans to invest $50 billion in the U.S. over the next five years to boost manufacturing and R&D. Basel, Switzerland-based Roche says the investments strengthen its U.S. footprint and should create more than 12,000 new jobs. That includes nearly 6,500 construction jobs, plus 1,000 jobs at new and expanded facilities. As part of…Thermo Fisher to invest $2B on U.S. manufacturing
Thermo Fisher Scientific announced today that it plans to invest an additional $2 billion in the U.S. over the next four years. The company said its investment should strengthen American innovation, manufacturing and economic competitiveness in the life sciences sector. It also comes as a number of companies consider investing in U.S. infrastructure amid potential…Sponsored Content See More >
Regulatory See More >

Putting patients first in clinical trials
Clinical trials offer clinicians a unique opportunity to lead advances in medicine, granting access to cutting-edge therapies that address unmet patient needs. They are a cornerstone of clinical practice that enhance patient outcomes, particularly for those with complex or refractory cases who have exhausted standard treatment options. Clinicians understandably prioritize the well-being and interests of…

Confidently navigate the transition from bench to batch

FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension

Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths

Eicos Sciences’ FDA-approved Aurlumyn promises to drastically reduce frostbite amputations
Learn how to rapidly develop smart and sustainable engineering and production processes See More >

Personalized medicine: advanced technology is saving lives
The concept of a “batch size one” in pharmaceutical manufacturing is closer than ever. There are companies advancing cell therapies in which body cells are used to heal or support the individual patient. These cells are manipulated or edited to change certain biological characteristics before being transferred to the patient. Personalized medicine is truly about…
Facility See More >

Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
Fujifilm Diosynth Biotechnologies, a major contract development and manufacturing organization (CDMO), has entered into a 10-year manufacturing supply agreement with Regeneron Pharmaceuticals, valued at over $3 billion. The deal has the Fujifilm subsidiary providing U.S.-based manufacturing for Regeneron, with planned expansions at Fujifilm’s large-scale biopharmaceutical manufacturing facility in Holly Springs, North Carolina. The Holly Springs…
Supply Chain See More >

Amgen to spend $900M to expand U.S. biopharma manufacturing
Amgen announced that it plans to invest $900 million to expand its pharmaceutical manufacturing facility in Ohio. The expansion brings the total number of jobs created to 750. Amgen’s total investment in Central Ohio now eclipses $1.4 billion. “Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today’s investment reinforces our ongoing…
Recalls See More >

Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Japanese health authorities searched a Kobayashi Pharmaceutical factory in Japan following reports of five deaths related to dietary supplements, Reuters reports. The plant inspection in western Japan is the second in recent days as health authorities inspected the company’s Osaka facility. In addition to the five reported deaths, there have been more than 100 hospitalizations…